Opendata, web and dolomites

HARMONY SIGNED

Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HARMONY project word cloud

Explore the words cloud of the HARMONY project. It provides you a very rough idea of what is the project "HARMONY" about.

standard    policy    platform    align    repository    appropriate    groups    differences    connect    excellence    pharmaceutical    reimbursement    hta    harmony    efpia    offensive    progress    optimize    public    decision    definitions    51    indicators    clinical    treatment    medical    medicines    health    private    trials    alliances    data    alliance    efficient    risk    advocacy    innovative    heterogeneous    unmet    patients    agencies    create    endpoint    cross    adults    hms    leaders    orchestrate    decisions    stakeholders    outcomes    outcome    big    care    survival    despite    made    regulatory    resourceful    treatments    patient    sharing    explorative    companies    cooperative    quality    experts    assemble    disorders    perspective    drug    sustainable    die    undoubtedly    healthcare    malignancies    hematology    desirable    benefit    children    profile    rates    pan    hematological    complications    improvement    neoplasms    analyze    countries    national    disabling    hm    44    empowers    collection    optimized    market    life    accelerated    clinicians   

Project "HARMONY" data sheet

The following table provides information about the project.

Coordinator
FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON 

Organization address
address: PARQUE SANTA CLARA
city: SORIA
postcode: 42002
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://www.harmony-alliance.eu/
 Total cost 42˙205˙587 €
 EC max contribution 20˙200˙000 € (48%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-06-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON ES (SORIA) coordinator 7˙987˙853.00
2    GMV SOLUCIONES GLOBALES INTERNET SAU ES (TRES CANTOS MADRID) participant 1˙203˙548.00
3    ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA IT (BOLOGNA) participant 1˙151˙652.00
4    FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA ES (VALENCIA) participant 1˙000˙062.00
5    EUROPEAN HEMATOLOGY ASSOCIATION NL (DEN HAAG) participant 831˙750.00
6    LEUKANET EV DE (RIEMERLING) participant 500˙000.00
7    SYNAPSE RESEARCH MANAGEMENT PARTNERS SL ES (MADRID) participant 500˙000.00
8    UNIVERSITAET ULM DE (ULM) participant 425˙000.00
9    STIFTUNG ELN FOUNDATION DE (MANNHEIM) participant 400˙133.00
10    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 400˙000.00
11    NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE UK (MANCHESTER) participant 400˙000.00
12    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 300˙000.00
13    UNIVERSITY OF YORK UK (YORK NORTH YORKSHIRE) participant 299˙926.00
14    BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE DE (BONN) participant 200˙000.00
15    AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS ES (MADRID) participant 199˙998.00
16    MLL MUNCHNER LEUKAMIELABOR GMBH DE (MUNCHEN) participant 199˙766.00
17    THE LYMPHOMA STUDY ASSOCIATION FR (PIERRE BENITE) participant 163˙100.00
18    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 158˙915.00
19    FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS ES (BARCELONA) participant 153˙348.00
20    UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA IT (ROMA) participant 152˙770.00
21    BARTS AND THE LONDON NHS TRUST UK (LONDON) participant 152˙750.00
22    GPOH GEMEINNUTZIGE GMBH DE (BERLIN) participant 151˙475.00
23    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 150˙000.00
24    FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS IT (BOLOGNA) participant 150˙000.00
25    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) participant 150˙000.00
26    GENOME RESEARCH LIMITED UK (LONDON) participant 150˙000.00
27    GROUP FOR RESEARCH ON ADULT ACUTE LYMPHOBLASTIC LEUKEMIA FR (PIERRE BENITE) participant 150˙000.00
28    GROUPE FRANCOPHONE DES MYELODYSPLASIES FR (PARIS) participant 150˙000.00
29    HEINRICH-HEINE-UNIVERSITAET DUESSELDORF DE (DUSSELDORF) participant 150˙000.00
30    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 150˙000.00
31    JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN DE (FRANKFURT AM MAIN) participant 150˙000.00
32    STICHTING VUMC NL (AMSTERDAM) participant 150˙000.00
33    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 150˙000.00
34    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 150˙000.00
35    OSPEDALE PEDIATRICO BAMBINO GESU IT (ROMA) participant 149˙976.00
36    VIB BE (ZWIJNAARDE - GENT) participant 149˙933.00
37    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 149˙613.00
38    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) participant 149˙500.00
39    MEDISAPIENS OY FI (HELSINKI) participant 149˙250.00
40    EUROPEAN RESEARCH INITIATIVE ON CLL EV DE (KOLN) participant 147˙748.00
41    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 146˙833.00
42    EUROPEAN ALLIANCE FOR PERSONALISED MEDICINE ASBL BE (BRUXELLES) participant 125˙000.00
43    EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION NL (LEIDEN) participant 100˙100.00
44    EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL BE (Brussels) participant 100˙000.00
45    Masarykova univerzita CZ (BRNO STRED) participant 100˙000.00
46    ABBVIE INC US (NORTH CHICAGO IL) participant 0.00
47    AMGEN BE (Bruxelles) participant 0.00
48    Bayer Pharma AG DE (Berlin) participant 0.00
49    CELGENE MANAGEMENT SARL CH (BOUDRY) participant 0.00
50    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
51    MENARINI RICERCHE SPA IT (POMEZIA) participant 0.00
52    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
53    TAKEDA DEVELOPMENT CENTRE EUROPE LTD UK (LONDON) participant 0.00

Map

 Project objective

Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in quality of life, many children and adults with HMs still die from these disorders or experience disabling complications. Therefore, improvement of health care of HMs is an unmet medical need. Thus, it is important to define and align standard and efficient sets of HMs outcomes to measure and evaluate HM data for clinical decisions, long term risk/benefit profile, reimbursement, value analysis, and clinical trials design. Improving outcome measures and endpoint definitions by taking into account “real-life” data and differences in cross-national healthcare practice will undoubtedly result in an optimized, sustainable and effective treatment delivery, as well as in desirable and innovative accelerated pathways for novel drug availability. All these challenges will be addressed within a pan-EU perspective by HARMONY (Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY), a comprehensive public-private European consortium of excellence.

HARMONY consortium is made up of 51 partners: 44 participants from 10 European countries and 7 pharmaceutical companies from the EFPIA. HARMONY aims to assemble, assess, connect, and analyze heterogeneous HM patient derived Big Data sets to define sets of outcome indicators that can be used for decision-making by key healthcare stakeholders. The consortium will orchestrate leading experts and working cooperative groups in HMs, European study alliances, pharmaceutical market leaders, patient advocacy groups, HTA and regulatory agencies, to: (i) optimize Europe-wide data collection and create a high-quality HM data repository for further explorative studies; (ii) establish a clinical data-sharing platform that empowers clinicians, patients and policy stakeholders to improve decision-making procedures and identify appropriate treatments to patients with HMs

 Deliverables

List of deliverables.
“Proof-of-Principle” study Other 2020-04-24 02:22:08
Case management: Security and Governance FW Other 2020-04-24 02:22:08
Guidance document on incidental findings Documents, reports 2020-04-24 02:22:08
Website and repository Other 2020-04-24 02:22:08
Communication strategy and plan Documents, reports 2020-04-24 02:22:08
HARMONY platform component deployment Other 2020-04-24 02:22:08
Definition of all sets of outcomes for individual HMs Other 2020-04-24 02:22:08
Point of contact/advisors Documents, reports 2020-04-24 02:22:08
Policy Health Stakeholder Feedback Forum (PHSFF) members identified and established Documents, reports 2020-04-24 02:22:08

Take a look to the deliverables list in detail:  detailed list of HARMONY deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Ellen P.B. de Waal
Hematology and Big Data
published pages: e17, ISSN: 2572-9241, DOI: 10.1097/hs9.0000000000000017
HemaSphere 1/1 2020-04-24
2018 Malcikova, J.; Tausch, E.; Rossi, D.; Sutton, L. A.; Soussi, T.; Zenz, T.; Kater, A. P.; Niemann, C. U.; Gonzalez, D.; Davi, F.; Gonzalez Diaz, M.; Moreno, C.; Gaidano, G.; Stamatopoulos, K.; Rosenquist, R.; Stilgenbauer, S.; Ghia, P.; Pospisilova, S.
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
published pages: , ISSN: 0887-6924, DOI: 10.5167/uzh-151201
\"Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 32 (5), pp.1070-1080. ⟨10.1038/s41375-017-0007-7⟩\" 1 2020-04-24
2020 Matteo Bersanelli, Ettore Mosca, Luciano Milanesi, Armando Bazzani, Gastone Castellani
Frailness and resilience of gene networks predicted by detection of co-occurring mutations via a stochastic perturbative approach
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-020-59036-w
Scientific Reports 10/1 2020-04-24
2019 Mattia D\'Agostino, Anders Waage, Juan-José Lahuerta, Uta Bertsch, Elena Zamagni, Lars Bullinger, Alessandra Larocca, Maria-Victoria Mateos, Niels W. C. J. Van De Donk, Hans Jürgen Salwender, Joan Bladé, Bronno van der Holt, Paola Tacchetti, Giovannino Ciccone, Sonja Zweegman, Hartmut Goldschmidt, Michele Cavo, Jesús San-Miguel, Pieter Sonneveld, Mario Boccadoro, Jesús María Hernández-Rivas
Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform
published pages: 1773-1773, ISSN: 0006-4971, DOI: 10.1182/blood-2019-124321
Blood 134/Supplement_1 2020-04-24
2019 L. Bullinger, P. Valk, J. Versluis, K. Metzeler, R. Ayala, Martinez J. Lopez, H. Dombret, P. Montesinos, J. Sierra, C. Preudhomme, F. Damm, K. Mills, J. Mayer, C. Thiede, M. T. Voso, S. Amadori, W. Hiddemann, G. Sanz, M. Vukcevic, P. Bacon, Villoria R. Medina, M. Van Speybroeck, R. Goodbody, R. Schulze-Rath, J.-E. Butler-Ransohoff, J. M. Hernández, F. Lo-Coco, B. Huntly, H. Döhner, G. Ossenkoppe
HARMONY ALLIANCE: EUROPEAN PUBLIC-PRIVATE DATA COLLECTION LEADS THE WAY - FIRST RESULTS OF THE “PROOF-OF-PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA
published pages: 451, ISSN: 2572-9241, DOI: 10.1097/01.hs9.0000562308.58356.23
HemaSphere 3 2020-04-24
2018 Ítalo Faria do Valle, Giulia Menichetti, Giorgia Simonetti, Samantha Bruno, Isabella Zironi, Danielle Fernandes Durso, José C. M. Mombach, Giovanni Martinelli, Gastone Castellani, Daniel Remondini
Network integration of multi-tumour omics data suggests novel targeting strategies
published pages: 10, ISSN: 2041-1723, DOI: 10.1038/s41467-018-06992-7
Nature Communications 9/1 2020-04-24
2017 Miklós Szócska, Sahan Jayawardana, Carin Smand, Tayyab Salimullah, Catherine Reed and Shahid Hanif
BIG DATA FOR BETTER OUTCOMES: SUPPORTING HEALTH CARE SYSTEM TRANSFORMATION IN EUROPE
published pages: , ISSN: 1356-1030, DOI:
Eurohealth — Vol.23 | No.1 | 2017 2020-04-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HARMONY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HARMONY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

FAIRplus (2019)

FAIRplus

Read More  

IDEA-FAST (2019)

Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory diseases

Read More